Quantcast

Latest treatment of Parkinson's disease Stories

2014-06-18 12:36:07

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Parkinson's Disease: World Drug Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/parkinson_s_disease_world_drug_industry_market_2014_2024.html Report DetailsTreating Parkinson's - how you find business trends, R&D, and revenue forecastsSee the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research...

2014-06-11 20:22:38

Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease NATICK, Mass., June 11, 2014 /PRNewswire/ -- Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise(TM) Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent improvement in motor scores, according to the latest one-year...

2014-06-10 20:23:03

Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease NATICK, Mass., June 10, 2014 /PRNewswire/ -- A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise(TM) Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease (PD). The CUSTOM-DBS clinical study demonstrated that shorter...

2014-04-30 08:33:57

Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phase 2/3 EASED study, included...

2014-04-23 16:30:11

EMERYVILLE, Calif., April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66(th) Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20130618/LA33709LOGO The poster (4009), is titled, "Safety and Efficacy Study of ADS-5102 (amantadine HCl) extended release capsules in Levodopa-Induced Dyskinesia...

2014-04-11 08:24:24

HAYWARD, Calif., April 11, 2014 /PRNewswire/ -- Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease (PD). After discussions with the FDA, the Company has...

2014-04-10 08:28:50

DUODOPA improves quality of life for those with advanced stages of disease MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA(® )(levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's - a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers. DUODOPA is approved...

2014-03-11 08:29:26

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease....


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related